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Abstract: Heart failure is increasing in prevalence, with approximately 26 million patients affected 
worldwide. This represents a significant cause of morbidity and mortality. Statistics regarding heart failure 
patient age, hospitalization likelihood, and mortality differ significantly by country. Heart failure patients 
are typically classified by ejection fraction, with distinct phenotypes associated with reduced ejection 
fraction (rEF) or preserved ejection fraction (pEF). Heart failure has a significant financial impact related to 
hospitalization, medication, and procedural expenses. The costs of heart failure also extend to the reduced 
quality of life conferred by heart failure symptoms. Management of heart failure includes a variety of 
interventions, including mechanical circulatory support (MCS). MCS, including left ventricular assist devices 
(LVADs), right ventricular assist devices (RVADs) and extracorporeal membrane oxygenation (ECMO), 
has been a means of managing end stage heart failure. Given the relative scarcity of transplant organs, the 
utilization of MCS, particularly as a bridge to transplantation (BTT) has grown significantly. In this review, 
we discuss statistics related to heart failure and MCS. We evaluate how patients are classified and examine 
global trends and regional differences. We then address MCS therapies, the costs associated with heart 
failure, the impact of heart failure on patient quality of life, and data regarding morbidity and mortality.
Keywords: Heart failure; prevalence; statistics; mechanical circulatory support (MCS); left ventricular assist device 
(LVAD)
Submitted Jan 31, 2020. Accepted for publication May 13, 2020.
doi: 10.21037/atm-20-1127
View this article at: http://dx.doi.org/10.21037/atm-20-1127
Introduction
Heart failure continues to plague the world; an estimated 
26 million people have heart failure (1). Of the deaths 
attributed to cardiovascular disease in 2016, approximately 
300,000 were estimated to be due to heart failure. Heart 
failure has been considered a pandemic, but primarily 
due to increasing prevalence (more people living with the 
disease), as opposed to increased incidence (more people 
diagnosed with the disease). In the United Kingdom (UK), 
prevalence increased 23% between 2002 and 2014. This 
increase in prevalence has been largely attributed to the 
improvements in medical management. In the United 
States of America (USA), 85.6 million adults have at least 
one type of cardiovascular disease, and it is estimated that 
1–3% of adults (over 6.2 million) were living with heart 
failure in 2016 (2), with prevalence increasing with age. By 
2030, this number is predicted to increase to more than 
8 million (3). Worldwide prevalence is similarly estimated to 
be between 1–3% in developed nations, with prevalence by 
country shown in Figure 1. After people are diagnosed with 
heart failure, the mortality risk is high—50% die within 
5 years, and 90% die within 10 years. When limited to an 
older population, utilizing the USA Medicare database, 
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there is 37% mortality within 1 year, suggesting increased 
mortality in an older subgroup, although this may simply 
represent lead time bias and/or reflect unique aspects of the 
USA healthcare system (4).
Global trends
There is a growing body of research that attempts 
to evaluate the regional differences in heart failure 
presentation and treatment. One of the major challenges to 
more broadly evaluating heart failure has been a lack of data 
from developing nations, but recent studies have attempted 
to compare the heart failure patient populations in Asia 
and sub-Saharan Africa to Europe and North America. 
Compared to patients in Europe and North America, 
patients in Asia tended to be younger (55 vs. 67 years 
mean), had fewer comorbidities [including chronic 
obstructive pulmonary disease (COPD), despite increased 
smoking rates], and had less restricted functional status (5). 
There also tended to be different etiologies—post infectious 
cardiomyopathies, including rheumatic heart disease, were 
more common in developing nations (although decreasing 
in incidence relative to non-infectious etiologies, such 
as hypertensive or ischemic cardiomyopathies) (6), while 
ischemic heart disease was predominant in Europe and 
North America. Heart failure patients in Asia, however, had 
higher rates of mortality and hospitalization. Within Asian 
countries, however, there are significant differences. Japan 
and South Korea had significantly lower mortality rates 
than that seen in Europe and North America, and India and 
the Philippines had significantly lower hospitalization rates 
European and North American heart failure patients (7). 
In sub-Saharan Africa, hypertensive heart disease was 
similarly common, with a pooled prevalence of 39.2%. 
Cardiomyopathy had a prevalence of 22.7%, rheumatic 
heart disease had 13.8%, and ischemic heart disease had 
a 7.2% prevalence. Right heart failure and pericardial 
disease were less common etiologies, with pulmonary 
tuberculosis and HIV as the leading causes, respectively. 
A high readmission rate (34.9%) was also noted (6). The 
Figure 1 Age-standardized global prevalence rates of cardiomyopathy and myocarditis per 100,000, both sexes, 2017. Global Burden of 
Disease Study 2017. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle: Institute for Health Metrics and Evaluation (IHME), 
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USA has noticed a downward trend in hospital admissions 
for heart failure, although readmission rates have increased 
(16.5% any-cause) (8) for those patients who have an 
initial hospitalization. Rather than readmission for heart 
failure itself, however, comorbidities tend to drive the 
hospitalization (4).
Patient characteristics
Patients with heart failure are categorized as either 
having preserved ejection fraction (pEF), defined by a 
left ventricular ejection fraction greater than 50% or 
reduced ejection fraction (rEF) defined by an ejection 
fraction less than 40%—these subcategories tend to differ 
phenotypically. Patients with pEF are more often older, 
female, and have higher rates of atrial fibrillation and 
hypertension. Patients with rEF are more commonly male 
and have a history of myocardial infarction (9). There is 
some thought to separate out patients with mid-range 
ejection fraction as well, as they tend to phenotypically 
mix symptoms that patients with preserved and rEF 
demonstrate. These patients with mid-range ejection 
fraction fall into one of three categories-patients who have 
improved ejection fraction (who were previously HFrEF), 
patients who have worsened ejection fraction (who were 
previously HFpEF), or patients who have consistent ejection 
fractions in the 40–50% range. Ninety percent of patients 
who fell into this mid-range category are either improved 
or worsened ejection fraction; only 10% were stably in the 
40–50% range. There have not been significant mortality 
differences noted between the groups, or at least, there have 
been inconsistencies across the literature (10).
There have been multiple attempts made to further sort 
patients beyond their ejection fraction. One study sorted 
patients with HFpEF into three phenotypic categories: 
young people with moderate diastolic dysfunction and 
normal brain natriuretic peptide levels, obese patients 
with diabetes, obstructive sleep apnea (OSA), and severely 
reduced left ventricular relaxation, and older patients with 
chronic kidney disease, pulmonary hypertension, and right 
ventricular dysfunction. Others have more simply classified 
patients with HFpEF by the presence or absence of specific 
comorbidities (2).
A recent study evaluated patient presentation and 
characteristics on a global scale, REPORT-HF. It found that 
patients commonly presented due to ischemia in Southeast 
Asia (25.6%), the Western Pacific (17.1%), the Middle East 
and Africa (16.2%). Hypertension, type 2 diabetes, and 
chronic kidney disease were common universally (63.6%, 
36.7%, and 20.3% respectively). Patients in Southeast 
Asia, Africa and the Middle East were noted to have worse 
baseline functional status [New York Heart Association 
(NYHA) class], while patients in Europe were noted to 
be much more likely to have atrial arrhythmia histories 
compared to patients in Southeast Asia (45.7% vs. 8.2%). 
COPD was a more common comorbidity in North America 
than elsewhere (27% vs. 19%) (5).
Mechanical circulatory support (MCS) in heart 
failure
MCS may be offered to patients with advanced heart 
failure. Multiple different registries and collectives have 
been created to share data about patients receiving MCS. 
The Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) was established 
in 2005. INTERMACS joined the Society of Thoracic 
Surgeons (STS) National Database as one of its components 
on January 1, 2018 (11). Additional databases include the 
European Registry for Patients with Mechanical Circulatory 
Support (EUROMACS) of the European Association for 
Cardio-Thoracic Surgery (EACTS) (12), the Japanese 
registry for Mechanically Assisted Circulatory Support 
(J-MACS) (13), and the UK Registry. The International 
Society for Heart and Lung Transplantation (ISHLT) 
Mechanically Assisted Circulatory Support (IMACS) has 
collected data since it originated in 2013. It currently 
collects data from STS-INTERMACS, EUROMACS, 
J-MACS, UK Registry, and 24 additional hospitals. The 
3rd IMACS report, with data through December 31, 2017, 
indicated it had collected data from over 16,000 patients 
from across the world (14). Data from these registries 
provide robust information on the MCS patient population. 
Additionally, long-term follow-up from prospective 
large trials such as MagLev Technology in Patients 
Undergoing Mechanical Circulatory Support Therapy 
with HeartMate 3 (MOMENTUM 3) (15) and Registry 
to Evaluate the HeartWare Left Ventricular Assist System 
(ReVOLVE) also provide valuable data (16). In addition 
to MCS, patients with heart failure may be candidates 
for heart transplantation. A Registry for Thoracic Organ 
Transplantation documents recipients of heart and heart-
lung transplants and is maintained by ISHLT, with over 
131,000 adult heart transplant recipients through June 
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2018. It is one of the most robust of the aforementioned 
databases (17).
First generation left ventricular assist devices (LVADs) 
were refined in the 1990s (HeartMate I, HeartMateVE, and 
HeartMate XVE) and were pulsatile volume displacement 
pumps which generated forward flow. Second generation 
LVADs (HeartMate-II) were continuous flow, rotary pumps. 
They used continuous axial flow to pull blood through 
the pump and generate forward flow. These devices were 
smaller and had fewer moving parts. The third generation 
LVADs (HeartMate-III and HeartWare VAD) used 
centrifugal pumps with a spinning impeller to propel blood 
and produce blood flow (18). As pumps continue to become 
more advanced, ongoing controversy persists regarding the 
appropriate time to implant the devices (11,19).
Categories have been developed to classify heart failure 
patients based on their clinical picture. The INTERMACS 
clinical profiles are used to describe various clinical pictures 
and serve as a shorthand for communication for severity of 
heart failure in patients that are receiving optimal medical 
therapy (20).
The IMACS database provides some insights into the 
number and types of devices over time. IMACS provides 
yearly data regarding centrifugal vs. axial devices over time 
2013–2017 with 884 vs. 2,279, 1,229 vs. 2,176, 1,339 vs. 
2,405, 1,371 vs. 2,064 and 1,360 vs. 1,179 respectively. Over 
this period, the drop in centrifugal pumps implanted in 
2017 was likely due to the MOMENTUM-3 trial and these 
patients being ineligible for inclusion in INTERMACS 
dataset. Over this time-period, 16,194 LVADs have 
been implanted and the proportion of patients fitting 
INTERMACS profiles 1 through 7 has remained about the 
same each year as shown in Table 1.
Heart transplantation continues to evolve. This evolution 
is driven, in part, by changes in the donor allocation systems 
with the use of extended-criteria donor hearts [donation 
after circulatory death (DCD), ex vivo perfusion supported 
hearts, hepatitis C]. The expansion of the donor criteria 
is because the demand for organs greatly outpaces supply. 
Yearly transplant volume has increased over the last decade. 
From 2010–2018, the median recipient age was 55 years, 
the median donor age was 35 years, approximately 40% of 
donor cause of death was head trauma, and approximately 
20% was stroke. The growth of pre-transplant MCS 
has been rapid from 2007 until present, but seems to be 
stabilizing at the current level of approximately 50%; 
LVADs make up approximately 45%, right ventricular assist 
devices (RVADs) approximately 3%, total artificial hearts 
(TAHs) approximately 1% and extracorporeal membranous 
oxygenation (ECMOs) approximately 1% (17). Figure 2 
provides additional information over time as it relates to 
heart transplantation from various types of MCS. Long 
term mortality is similar for transplantation from MCS, 
other than ECMO as shown in Figure 3.
Availability of LVADs is functionally limitless, but heart 
transplants are limited by the donor supply. Ongoing 
consideration of ways to expand the donor pool is taking 
place. The first reported heart transplant following 
donation after circulatory death (DCD) took place in 
a pediatric series in 2008 (21). The expansion of this 
technique has continued as a way to expand the limited 
heart donor pool. Importantly, the technique of heart 
transplant following DCD has generated ethical concerns 
and controversy (22,23). Most donations of organs are 
after brain-stem determined death, but there are a growing 
number of centers around the world including Australia, 
UK, and Belgium (24). Centers that are performing heart 
transplant after DCD have been having comparable short-
Table 1 INTERMACS profile descriptions (14)
INTERMACS profile Description LVAD implantation percentage 2013-17
1 Critical cardiogenic shock 17%
2 Progressive decline, despite intravenous inotropic support 33%
3 Stable on intravenous inotropic support 34%
4 Resting symptoms on oral therapy 13%
5 Exertion intolerant, comfortable at rest, but no activity 2%
6 Exertion limited 1%
7 Advanced New York Heart Association (NYHA) III symptoms 1%
INTERMACS, the Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device.
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term outcomes (25).
Financial impact
The costs of heart failure on a global scale are difficult to 
ascertain. There are numerous challenges to comparing 
costs across countries. Challenges cited include how the 
disease itself is defined, how the treatments are valued, and 
where the data are sourced. A study primarily evaluating 
North America, Europe, and Asia found that annual costs 
ranged (in international dollars) from $868 to $25,532, with 
an increase in cost noted as NYHA classification increased 
(with NYHA class IV patients comprising 70% of heart 
failure expenditures), increased with comorbidities (in 
particular diabetes mellitus), and increased toward the end 
of life. The country of residence has been significant, with 
the highest costs incurred in Germany and the USA (26).
The intersection of the increasing prevalence of heart 
failure with the rising cost of healthcare technology 
was predicted as early as 1985 by a working group at 
the National Heart, Lung, and Blood Institute who 
hypothesized that the future advent of MCS would be an 
expensive therapy to provide and afford (27). This prescient 
prediction has sparked debates and studies over the last 
35 years as technological advances in advanced heart 
failure therapies have grown. Prior to the groundbreaking 
REMATCH trial, bridge to transplant (BTT) LVAD 
implantation was deemed reasonable because of the 
durability of eventual heart transplant survival and the 
abysmal outcomes of medical management for advanced 
heart failure (28). However, the dramatic mortality benefit 
demonstrated in the REMATCH trial, coupled with the 
rate-limiting availability of donor hearts, portended an 
increased utilization of LVAD therapy for destination 
therapy (DT) and a concomitant increase in related direct 
and indirect healthcare costs. These predictions were born 
out with the FDA approval of BTT therapy in 2008, and 
DT therapy in 2010. The direct and indirect healthcare 
costs of heart failure are predicted to increase dramatically 
with total direct and indirect costs expected at nearly $53 
billion and $17 billion, respectively, by 2030 (29).
The early studies reporting costs and cost-effectiveness 
of LVADs are likely not relevant because of the significant 
differences in design between first and current third 
generation devices. However, these findings do provide a 
reference point for cost analysis. Most early cost analyses 
report daily costs or incremental costs without taking into 
account efficacy. A Danish study calculated cost per life-
Figure 2 Adult heart transplants % of patients bridged with MCS (LVAD, RVAD, TAH, ECMO) by year and device type (17). From: 
International Society for Heart and Lung Transplantation. Available online: https://ishltregistries.org/downloadables/slides/2019/heart_
adult.pptx; with permission. MCS, mechanical circulatory support; LVAD, left ventricular assist device; RVAD, right ventricular assist 
device; TAH, total artificial heart; ECMO, extracorporeal membrane oxygenation.
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year saved as $48,000 (30), while a study from the UK 
reported the cost per quality adjusted life year (QALY) to 
be $78,000 for BTT usage (31). Along the journey from 
early cost analysis, evidence accrued which questioned 
the cost effectiveness of second-generation devices. A 
more robust analysis in the UK of the HeartMate II 
for BTT demonstrated a significantly increased cost of 
£258,922 ($414,275) per QALY compared to conventional 
management until heart transplantation (32). The reduced 
cost efficacy of the HeartMate II was presumed to be due 
to the improved survival of heart transplant recipients, and 
the significant acquisition costs of the device hardware. 
The cost-effectiveness of the third generation HeartWare 
was compared to the HeartMate II in the UK for BTT 
patients which demonstrated both improved efficacy and 
reduced costs of HeartWare device as demonstrated by an 
incremental cost-effective ratio (ICER) of $38,697 over 
the lifetime of the patient because of the improved survival 
to transplantation, which incurs greater costs (33). ICER 
serves as a robust cost-utility analysis to compare the costs 
per QALY gained between interventions.
Although, no direct head-to-head comparison has 
been performed, the cost-effectiveness of LVAD DT 
has demonstrated to be less convincing in comparison 
to BTT therapy. A variety of cost analyses of LVAD 
DT compared to medical management have reported 
significantly increased costs per QALY. Utilizing data 
obtained from the REMATCH trial, investigators reported 
the ICER of $198,184 per QALY compared to medical 
management, which equates to a 75% reduction in ICER, 
from $802,702 per QALY, for first generation, pulsatile 
flow device (34). USA Medicare data, likewise, has reported 
comparable ICER of $209,400 per QALY; of which, a 
significant factor is the increase in readmission rates after 
LVAD implantation (35). Because of these increased costs 
associated with both device implantation and readmissions, 
more cost-conscious healthcare systems, such as Canada 
and the UK, have resisted the expansion of DT LVAD 
therapy.
Quality of life impact
Quality of life for heart failure patients is typically 
measured utilizing instruments such as the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) or the Minnesota 
Living with Heart Failure Questionnaire (MLHFQ). 
These instruments utilize questions regarding activities of 
daily living, shortness of breath, and edema to ascertain 
the impact of heart failure on patient lives. Generally, 
scores tend to improve over time, but few medical aspects 
Figure 3 Adult heart transplants Kaplan-Meier survival by pre-transplant MCS use (transplants: January 2009–June 2016) (17). From: 
International Society for Heart and Lung Transplantation. Available online: https://ishltregistries.org/downloadables/slides/2019/heart_
adult.pptx; with permission. MCS, mechanical circulatory support; LVAD, left ventricular assist device; RVAD, right ventricular assist 













0  1  2  3  4  5  6  7
Years
No pair-wise comparisons were significant at P<0.05 except ECMO 
vs. LVAD continuous and ECMO vs. No LVAD.
LVAD pulsatile (N=144)
LVAD + RVAD pulsatile (N=160)




Annals of Translational Medicine, Vol 8, No 13 July 2020 Page 7 of 10
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(13):827 | http://dx.doi.org/10.21037/atm-20-1127
improve the scores. Exercise and spironolactone have 
demonstrated increased scores compared to control or 
placebo. Ultimately, the functional limitations due to heart 
failure (as classified by the New York Heart Association) 
is a significant predictor of readmission and mortality (2). 
Patients in Japan were scored using the Barthel index, 
an instrument that assesses a patient’s ability to perform 
activities of daily living. Approximately 43.4% of patient 
scores worsened, which, along with low baseline scores, 
correlated with being discharged to a non-home location, to 
require a longer hospitalization, be readmitted, and suffer 
mortality (36).
Following LVAD implantation, there is an initial 
decline in quality of life indicators followed by substantial 
improvement. A study utilizing the INTERMACS registry 
and KCCQ survey data noted a baseline median score of 
34.6 (scored 0–100, with 100 representing no impact on 
quality of life) with median scores of 14.3 at 3 months, 
28.1 at 6 months, 41.1 at 9 months, at 63.8 at 1 year. There 
is some suggestion that there is a large improvement in 
quality of life following MCS utilization. These numbers 
may be biased as there was a significant association between 
3-month KCCQ scores and mortality, but comparison of 
mortality across score quartiles did not differ significantly 
beyond this point (37).
Mortality data and trends
Considering the high mortality associated with heart 
failure, patient outcomes are closely studied, particular in 
Europe and North America. OPTIMIZE-HF, IMPACT-
HF, EFFECT, and the EuroHeart Failure Survey have 
demonstrated no significant difference in mortality or 
rehospitalization between patients with reduced and pEF. 
OPTIMIZE-HF reported mortality rates of 37.5%, 35.1% 
and 35.6% at 1 year for patients with reduced, mid-range, 
and pEF in patients in the USA. EFFECT demonstrated 
similar numbers for 1-year mortality for patients with 
reduced and pEF (25.5% and 22.2%) in the Canadian 
population. The EuroHeart Failure Survey noted an 
estimated 1-year mortality rate of 23.6% for acute heart 
failure and 6.4% for chronic heart failure. The Swedish 
Heart Failure Registry was utilized 12 years of data to 
compare mortality between patients with reduced and pEF 
and found no significant difference. One-year all-cause 
mortality for heart failure patients in Spain was 14%, but 
found that those patients with recent hospitalization faced 
an increased likelihood (24%) (38).
In other areas of the world, data are more complete. 
Thirty-day mortality rate in China is reported to be 5.3%, 
while in Taiwan 3.9%. In Singapore, a 2.5% mortality rate 
over 7 years was listed. A study of Korean patients reported 
9.2% mortality at 1 year, and a study of patients in Japan 
reported 8.9% mortality in patients with HFrEF and 11.6% 
mortality in patients with HFpEF at 1 year. Numbers from 
South America and Australia are more similar to those 
reported in Europe and North America, with a respective 
1-year mortality of 24.5% and 20.5–20.7% (10).
A multicenter European study evaluating mortality and 
guideline adherence by physicians found that patients who 
saw physicians who followed guideline-based practice were 
93% as likely to die as those patients who did not follow 
guideline-based practice over the 18-month period of the 
study (39).
Data would suggest that there has been a significant 
decline in mortality secondary to heart failure over the 
past 50 years. A study from the USA demonstrated a 70% 
decline from 206 per 100,000 in 1968 to 62 per 100,000 
in 2017. This rate, however, has not significantly changed 
since 2011 (40).
For patients who have undergone MCS, survival is 
approximately 83% at 1 year (11). The INTERMACS 
classification system, as previously mentioned, is the 
most common method of describing MCS candidates. 
However, more specific predictive tools have been 
developed for mortality and outcomes following LVAD 
implantation (37). The Destination Therapy Risk Score 
was initially utilized, but was found to be poorly predictive 
in continuous flow VAD patients (41). The HeartMate 
II Risk Score (HRMS) was designed to predict 90-day 
mortality in patients undergoing LVAD implantation and 
was defined as a function of age, international normalized 
ratio, albumin, creatinine, and center volume. Stratification 
of INTERMACS class I patients into low, mid, and high 
categories predicts a 2-year mortality of 8%, 12%, and 
32%, respectively, with a c-statistic of 0.7 (42). These data 
have had limited reproducibility, with minimal difference in 
mortality noted between the stratified groups when applied 
to other cohorts. A Bayesian model, Cardiac Outcomes 
Risk Assessment (CORA), has been developed that utilizes 
(I) intervention within the last 48 hours, (II) creatinine, 
(III) events experienced during the hospitalization closest 
to LVAD implantation, (IV) previous cardiac operations, 
(V) IV inotrope therapy agent, (VI) primary diagnosis, 
(VII) hemoglobin, (VIII) LVAD device strategy, and 
(IX) INTERMACS profile to predict mortality with a 
Bowen et al. Statistics of heart failure and mechanical support
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(13):827 | http://dx.doi.org/10.21037/atm-20-1127
Page 8 of 10
c-statistic of 0.81 for 90-day mortality and 0.79 for 1 year 
mortality. The most impactful events on mortality were 
cardiac arrest, intubation, dialysis, extracorporeal life 
support, feeding tube placement, and balloon pump 
utilization (41). As machine learning becomes more 
integrated into predictive modeling in the healthcare 
system, there will likely be additional models to predict 
heart failure associated mortality (43).
Conclusions
In summary, the increased prevalence of heart failure 
has prompted increasing interest in both the medical 
management and advanced therapies because of significant 
effect on quality of life, mortality, and the economic burden 
imposed. Continued international cooperation in registry 
data collection and well-designed clinical outcomes trial 
will further identify the best timing of therapies. The 
tremendous growth in mechanical support for heart failure 
has perhaps over-shadowed medical management. However, 
the future of genomic-centered, patient-specific therapies 
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